Oberacher-Velten, I. M. and Helbig, H. (2010) VEGF Antibodies as Therapy for Retinopathy of Prematurity. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 227 (9). pp. 694-700. ISSN 0023-2165, 1439-3999
Full text not available from this repository. (Request a copy)Abstract
Retinopathy of prematurity (ROP) is one of the three leading causes of legal blindness in childhood in the developed countries. Improved neonatal care has resulted in the increased survival of extremely immature infants at high risk to develop ROP. Current treatment for ROP with laser may prevent blindness by causing involution of pathological vessels and thus inhibit the development of retinal detachment. But this coagulation of the avascular retina is a destructive therapy and does not otherwise ameliorate retinal development. Recent reports have described vascular endothelial growth factor antibodies as therapy for ROP. This article reports our own experience with this new therapy and gives an overview of the recent literature.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DIODE-LASER PHOTOCOAGULATION; ENDOTHELIAL GROWTH-FACTOR; THRESHOLD RETINOPATHY; INTRAVITREAL BEVACIZUMAB; MULTICENTER TRIAL; ZONE-I; CRYOTHERAPY; ROP; POPULATION; INJECTION; retinopathy of prematurity; anti-VEGF; bevacizumab; vascular endothelial growth factor |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Augenheilkunde |
| Depositing User: | Petra Gürster |
| Date Deposited: | 17 Apr 2020 08:35 |
| Last Modified: | 17 Apr 2020 08:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/24267 |
Actions (login required)
 |
View Item |
